Clozapine-resistant psychosis, smoking, and caffeine: managing the neglected effects of substances that our patients consume every day.
暂无分享,去创建一个
Gavin McKay | A. Grandison | Luiz Dratcu | Alistair Grandison | Adekunle Bamidele | Vinodini Vasudevan | L. Dratcu | G. McKay | A. Bamidele | V. Vasudevan
[1] O. Spigset,et al. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. , 2000, British journal of clinical pharmacology.
[2] P. Keck,et al. Definition, evaluation, and management of treatment refractory mania. , 2001, Psychopharmacology bulletin.
[3] J. de Leon,et al. Caffeine intake in outpatients with schizophrenia. , 2004, Schizophrenia bulletin.
[4] H. Meltzer,et al. An overview of the mechanism of action of clozapine. , 1994, The Journal of clinical psychiatry.
[5] F. Bengtsson,et al. Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report. , 1999, Therapeutic drug monitoring.
[6] S. Sandberg. Hyperkinetic or Attention Deficit Disorder , 1996, British Journal of Psychiatry.
[7] Amin Rostami-Hodjegan,et al. Influence of Dose, Cigarette Smoking, Age, Sex, and Metabolic Activity on Plasma Clozapine Concentrations: A Predictive Model and Nomograms to Aid Clozapine Dose Adjustment and to Assess Compliance in Individual Patients , 2004, Journal of clinical psychopharmacology.
[8] J. Kane. Factors which can make Patients Difficult to Treat , 1996, British Journal of Psychiatry.
[9] B. Tang,et al. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. , 2001, Journal of Clinical Psychopharmacology.
[10] Disciplinary Committee,et al. Royal Pharmaceutical Society of Great Britain , 2002 .
[11] M. Frye,et al. Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. , 1998, Journal of affective disorders.
[12] Carlos Pato,et al. Effects of the acute administration of caffeine in patients with schizophrenia , 1990, Biological Psychiatry.
[13] P. Delgado. How antidepressants help depression: mechanisms of action and clinical response. , 2004, The Journal of clinical psychiatry.
[14] R. Kerwin,et al. Amisulpride augmentation of clozapine: an open non‐randomized study in patients with schizophrenia partially responsive to clozapine , 2004, Acta psychiatrica Scandinavica.
[15] E. Vieta,et al. An open-label study of amisulpride in the treatment of mania. , 2005, The Journal of clinical psychiatry.
[16] A. Grandison,et al. Substance use history taking by trainee psychiatrists: “There is a tide in the affairs of men…” , 2001, Irish Journal of Psychological Medicine.
[17] J R Hughes,et al. Prevalence of smoking among psychiatric outpatients. , 1986, The American journal of psychiatry.
[18] R. Griffiths,et al. The Role of Dopamine in the Behavioral Effects of Caffeine in Animals and Humans , 1997, Pharmacology Biochemistry and Behavior.
[19] E. Perucca,et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics , 2000, Psychopharmacology.
[20] J. Kennedy,et al. CYP1A2 Activity as Measured by a Caffeine Test Predicts Clozapine and Active Metabolite Norclozapine Steady-State Concentration in Patients With Schizophrenia , 2001 .
[21] P. Keck. Defining and improving response to treatment in patients with bipolar disorder. , 2004, The Journal of clinical psychiatry.
[22] J. Kopitz,et al. Plasma amisulpride levels in schizophrenia or schizoaffective disorder , 2004, European Neuropsychopharmacology.
[23] B. Soares,et al. Amisulpride for schizophrenia. , 2002, The Cochrane database of systematic reviews.
[24] K. Brøsen,et al. Drug Interactions and the Cytochrome P450 System , 1995 .
[25] R. C. Pierce,et al. The mesolimbic dopamine system: The final common pathway for the reinforcing effect of drugs of abuse? , 2006, Neuroscience & Biobehavioral Reviews.
[26] U. Fuhr,et al. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking , 2004, Clinical pharmacology and therapeutics.
[27] K. Brøsen. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. , 1995, Clinical Pharmacokinetics.